#ENDVOC researchers at @igtp.bsky.social and #ISGlobal have discovered that the sequence of diseases a person experienced before #SarsCov2 infection influences their risk of developing #LongCOVID.

🔗 https://f.mtr.cool/vzzecmuyqn

END-VOC Issues Strategic Recommendations to Strengthen Cohort-Based Research for Future Health Threats The recommendations call on researchers, authorities and funders to ensure consistent protocols, robust infrastructure, and flexible ethical and funding mechanisms Longitudinal cohort studies, which track individuals over time, have proven invaluable for understanding disease progression, identifying risk factors, and evaluating interventions such as vaccines. During the COVID-19

Integrating data from diverse cohorts is challenging, but crucial, to respond to future health threats.

Our new #ENDVOC policy paper highlights lessons learned and offers recommendations to strengthen global research and evidence-based action.

🟠 https://f.mtr.cool/vziwozxtnp

#ENDVOCproject

The #ENDVOC consortium is holding its final face-to-face meeting in Lisbon, hosted by GIMM Foundation.

🌟Exciting achievements and ongoing work presented by partners, including harmonisation of cohort data, estimates of #LongCovid burden and economic impact.

#COVID19 | @ucl.ac.uk

🔴Muy interesante 👇🏻

📍El proyecto europeo #ENDVOC, en el que participa @isglobal.org, ha desarrollado el informe "#COVIDpersistente y síndromes postinfecciosos: Evidencia, impacto y recomendaciones de políticas"

📑 ▶️ 🔗 endvoc.eu/the-endvoc-c...

New study by #ENDVOC consortium suggests that #LongCovid may be linked to stronger or prolonged immune activation upon initial infection.

The study followed over 2,000 participants from the Virus Watch cohort.

🟠 endvoc.eu/endvoc-study...

“Our data suggest that updated vaccines are key, especially for those previously infected,” says #ISGlobal researcher @moncunill.bsky.social.

The study is part of the Horizon Europe #ENDVOC project, which uses global cohorts to analyse the impact of #COVID variants.

🔗 endvoc.eu

A Switch to IgG4 Antibodies After COVID-19 Vaccination May Increase the Risk of Breakthrough Infections For over three years, ENDVOC researchers analysed the quantity and function of different antibody classes in a cohort of healthcare workers who received mRNA vaccine booster doses    During the COVID-19 pandemic, a variety of vaccines were developed, with mRNA vaccines leading the way in Western countries. These vaccines

#ENDVOC research suggests high IgG4 antibody levels after repeated mRNA boosters may increase the risk of breakthrough #COVID infections. Should we rethink vaccine schedules?

A Switch to IgG4 Antibodies After COVID-19 Vaccination May Increase the Risk of Breakthrough Infections For over three years, ENDVOC researchers analysed the quantity and function of different antibody classes in a cohort of healthcare workers who received mRNA vaccine booster doses    During the COVID-19 pandemic, a variety of vaccines were developed, with mRNA vaccines leading the way in Western countries. These vaccines

"Booster doses remain essential for protection [against #COVID19], but our findings highlight the need to reassess vaccine formulations and schedules."

#ENDVOC

A Switch to IgG4 Antibodies After COVID-19 Vaccination May Increase the Risk of Breakthrough Infections For over three years, ENDVOC researchers analysed the quantity and function of different antibody classes in a cohort of healthcare workers who received mRNA vaccine booster doses    During the COVID-19 pandemic, a variety of vaccines were developed, with mRNA vaccines leading the way in Western countries. These vaccines

For over 3 years, #ENDVOC followed healthcare workers to study post-vaccination immunity against #COVID19. Their findings raise new questions about long-term protection.

The highly mutated #SARS-CoV-2 BA.2.86 (Pirola) variant evades the action of many neutralizing antibodies, but remains largely recognised by T cells, shows a new joint study by #endvoc researchers at #ISGlobal and @ucl.ac.uk.

🟠 endvoc.eu/t-cells-hold...